The race to find an effective treatment for coronavirus disease 2019 (COVID-19) is still on, with only two treatment options currently authorized for emergency use and/or recommended for patients hospitalized with severe respiratory symptoms: low-dose dexamethasone and remdesivir. The USA decision to stockpile the latter has resulted in widespread condemnation and in similar action being taken by some other countries. In this commentary we discuss whether stockpiling remdesivir is justified in light of the currently available evidence.
All Keywords
【저자키워드】 COVID-19, Dexamethasone, SARS-CoV-2, coronavirus, Antiviral, Remdesivir, stockpiling, 【초록키워드】 Dexamethasone, Treatment, coronavirus disease, Coronavirus disease 2019, Remdesivir, low-dose, respiratory, USA, Emergency use, Evidence, respiratory symptoms, severe respiratory symptoms, widespread, effective, patients hospitalized, 【제목키워드】 USA,
【저자키워드】 COVID-19, Dexamethasone, SARS-CoV-2, coronavirus, Antiviral, Remdesivir, stockpiling, 【초록키워드】 Dexamethasone, Treatment, coronavirus disease, Coronavirus disease 2019, Remdesivir, low-dose, respiratory, USA, Emergency use, Evidence, respiratory symptoms, severe respiratory symptoms, widespread, effective, patients hospitalized, 【제목키워드】 USA,
코로나바이러스 질병 2019(COVID-19)에 대한 효과적인 치료법을 찾기 위한 경쟁은 여전히 진행 중이며 현재 응급 사용이 승인되거나 중증 호흡기 증상으로 입원한 환자에게 권장되는 두 가지 치료 옵션인 저용량 덱사메타손과 렘데시비르만 있습니다. 후자를 비축하기로 한 미국의 결정은 광범위한 비난을 초래했으며 일부 다른 국가에서도 유사한 조치를 취하고 있습니다. 이 논평에서 우리는 현재 사용 가능한 증거에 비추어 렘데시비르를 비축하는 것이 정당한지 여부를 논의합니다.